2018 Volume 9 Issue 1 Pages 58-62
We performed a series of continuous renal replacement therapy (CRRT) using HEMOFEEL®SHG-1.0 (SHG) or EXCELFLO®AEF-10 (AEF), both made of polysulfone membrane. During CRRT treatments, we focused on the relationship between clotting in the hemofilter and pressure variation during the treatment. We analyzed the difference between SHG and AEF with respect to these aspects. 【Result】Inlet pressure levels in the SHG group tended to be sustainably high compared with those in the AEF group, but there were no differences between the groups for returned pressure levels. The differential pressure (i.e., return pressure-inlet pressure) of the SHG group was significantly higher than that of the AEF group. In the SHG group, inlet pressure levels increased 16h after the start of treatment. Conversely, transmembrane pressure levels did not increase and were maintained within a 20–30 mmHg. Furthermore, residual clots in the hemofilters at the end of treatments were observed in two out of three cases in the AEF group, but were not observed in the SHG group. The present study suggests that SHG has a higher differential pressure leading to superiority in avoiding clotting in the hemofilter compared with AEF and may be explained by the structural design of SHG that promotes high blood linear velocity. 【Conclusion】Use of SGH during CRRT may possibly be a favorable option for avoiding clotting in the hemofilter.
